Role of Nasopharyngeal Airway in Management of Craniofacial Syndrome-Associated Upper Airway Obstruction in Children.

IF 2.4 3区 医学 Q2 DENTISTRY, ORAL SURGERY & MEDICINE
Samara Thambar, Matthew D Wong, Sandra Schilling, Nitin Kapur
{"title":"Role of Nasopharyngeal Airway in Management of Craniofacial Syndrome-Associated Upper Airway Obstruction in Children.","authors":"Samara Thambar, Matthew D Wong, Sandra Schilling, Nitin Kapur","doi":"10.1111/ocr.12872","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Upper airway obstruction (UAO) management in children, particularly those with associated anatomical mid-face structural differences, poses a significant challenge. This study describes using a nasopharyngeal airway (NPA) in managing infants with severe upper airway obstruction.</p><p><strong>Methods: </strong>Infants discharged home from Queensland Children's Hospital with an NPA in situ for the management of upper airway obstruction were retrospectively evaluated for clinical and demographic parameters, underlying diagnoses and respiratory support, including NPA insertion details and comorbidities.</p><p><strong>Results: </strong>Sixty-seven children (24 male) were included with a median age at NPA insertion of 24 (IQR 7-59) days and a median duration of NPA use of 229.1 (IQR 151.50-297.75) days. Fifty-two (77.6%) had Pierre Robin sequence. Other diagnoses included CHARGE syndrome, Treacher Collins syndrome, Stickler syndrome, Crouzon syndrome, Bohring-Opitz syndrome, isolated cleft palate, Beckwith-Wiedemann syndrome, Chromosome 3 deletion and VACTERL association. Four infants required tracheostomy, and no complications related to NPA use were reported. Those with oximetry and polysomnography data showed improving indices following NPA insertion [pre NPA median (IQR) SpO<sub>2</sub>: 95.9% (94.73-97.73), AHI: 51.40 (44.50-69.45), OAHI 65.9 (56.45-73.35) and TcCO<sub>2</sub> (mmHg) 65.70 (61.95-67.30) vs. post-NPA median (IQR) SpO<sub>2</sub>: 97.1% (96.19-97.9), AHI: 12.20 (11.25-24.35), OAHI 10.20 (6.12-5.62) and TcCO<sub>2</sub> (mmHg) 52.40 (47.90-58.40)].</p><p><strong>Conclusion: </strong>Our findings highlight the effectiveness and safety of NPA as a noninvasive management option for severe upper airway obstruction in children, particularly in those with anatomical midface structural differences. Further research and larger studies are warranted to confirm these findings and optimise management strategies for these patients.</p>","PeriodicalId":19652,"journal":{"name":"Orthodontics & Craniofacial Research","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Orthodontics & Craniofacial Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ocr.12872","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Upper airway obstruction (UAO) management in children, particularly those with associated anatomical mid-face structural differences, poses a significant challenge. This study describes using a nasopharyngeal airway (NPA) in managing infants with severe upper airway obstruction.

Methods: Infants discharged home from Queensland Children's Hospital with an NPA in situ for the management of upper airway obstruction were retrospectively evaluated for clinical and demographic parameters, underlying diagnoses and respiratory support, including NPA insertion details and comorbidities.

Results: Sixty-seven children (24 male) were included with a median age at NPA insertion of 24 (IQR 7-59) days and a median duration of NPA use of 229.1 (IQR 151.50-297.75) days. Fifty-two (77.6%) had Pierre Robin sequence. Other diagnoses included CHARGE syndrome, Treacher Collins syndrome, Stickler syndrome, Crouzon syndrome, Bohring-Opitz syndrome, isolated cleft palate, Beckwith-Wiedemann syndrome, Chromosome 3 deletion and VACTERL association. Four infants required tracheostomy, and no complications related to NPA use were reported. Those with oximetry and polysomnography data showed improving indices following NPA insertion [pre NPA median (IQR) SpO2: 95.9% (94.73-97.73), AHI: 51.40 (44.50-69.45), OAHI 65.9 (56.45-73.35) and TcCO2 (mmHg) 65.70 (61.95-67.30) vs. post-NPA median (IQR) SpO2: 97.1% (96.19-97.9), AHI: 12.20 (11.25-24.35), OAHI 10.20 (6.12-5.62) and TcCO2 (mmHg) 52.40 (47.90-58.40)].

Conclusion: Our findings highlight the effectiveness and safety of NPA as a noninvasive management option for severe upper airway obstruction in children, particularly in those with anatomical midface structural differences. Further research and larger studies are warranted to confirm these findings and optimise management strategies for these patients.

鼻咽通气道在治疗颅面综合征相关儿童上呼吸道阻塞中的作用。
导言:儿童上气道阻塞(UAO)的治疗,尤其是那些伴有面中部解剖结构差异的儿童,是一项巨大的挑战。本研究介绍了使用鼻咽通气道(NPA)治疗严重上气道梗阻婴儿的方法:方法:对从昆士兰儿童医院出院回家并在原位安装了 NPA 以治疗上气道阻塞的婴儿进行了回顾性评估,包括临床和人口学参数、基础诊断和呼吸支持,包括 NPA 插入细节和合并症:共纳入 67 名儿童(24 名男性),插入 NPA 时的中位年龄为 24 天(IQR 7-59 天),使用 NPA 的中位持续时间为 229.1 天(IQR 151.50-297.75 天)。52例(77.6%)患者患有皮埃尔-罗宾序列。其他诊断包括CHARGE综合征、特雷撤-科林斯综合征、斯蒂克勒综合征、克鲁宗综合征、博林-奥皮茨综合征、孤立性腭裂、贝克维茨-韦德曼综合征、染色体3缺失和VACTERL关联。有四名婴儿需要进行气管造口术,但未报告与使用 NPA 有关的并发症。有血氧饱和度和多导睡眠监测数据的婴儿在植入 NPA 后各项指标均有所改善[NPA 前 SpO2 中位数(IQR):95.9%(94.73%)]:95.9% (94.73-97.73), AHI: 51.40 (44.50-69.45), OAHI 65.9 (56.45-73.35) and TcCO2 (mmHg) 65.70 (61.95-67.30) vs. NPA 后中位数(IQR)SpO2:97.1%(96.19-97.9)、AHI:12.20(11.25-24.35)、OAHI 10.20(6.12-5.62)和 TcCO2(mmHg)52.40(47.90-58.40)]:我们的研究结果凸显了 NPA 作为儿童严重上气道阻塞的无创治疗方案的有效性和安全性,尤其是对于那些存在解剖学中面结构差异的儿童。为了证实这些研究结果并优化这些患者的管理策略,有必要开展进一步的研究和更大规模的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Orthodontics & Craniofacial Research
Orthodontics & Craniofacial Research 医学-牙科与口腔外科
CiteScore
5.30
自引率
3.20%
发文量
65
审稿时长
>12 weeks
期刊介绍: Orthodontics & Craniofacial Research - Genes, Growth and Development is published to serve its readers as an international forum for the presentation and critical discussion of issues pertinent to the advancement of the specialty of orthodontics and the evidence-based knowledge of craniofacial growth and development. This forum is based on scientifically supported information, but also includes minority and conflicting opinions. The objective of the journal is to facilitate effective communication between the research community and practicing clinicians. Original papers of high scientific quality that report the findings of clinical trials, clinical epidemiology, and novel therapeutic or diagnostic approaches are appropriate submissions. Similarly, we welcome papers in genetics, developmental biology, syndromology, surgery, speech and hearing, and other biomedical disciplines related to clinical orthodontics and normal and abnormal craniofacial growth and development. In addition to original and basic research, the journal publishes concise reviews, case reports of substantial value, invited essays, letters, and announcements. The journal is published quarterly. The review of submitted papers will be coordinated by the editor and members of the editorial board. It is policy to review manuscripts within 3 to 4 weeks of receipt and to publish within 3 to 6 months of acceptance.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信